Adocia stock breaks through its 2.62 € support before a rebound during the session
The Lyon-based biotech specializing in insulin formulations regains ground on Tuesday, after several weeks of marked downward pressure. This rebound occurs in a degraded technical context, with a security that remains far from its moving averages.
A surge that compensates only a fraction of a quarterly decline of 34%
Adocia gains 6.16% during the session at 2.79 €, after closing the previous day at 2.628 €. This rebound places the security among the strongest gains on the CAC All Shares on Tuesday, in a nearly stable Paris market (the CAC 40 advances 0.21% during the session). Today's increase, however, barely attenuates a quarterly decline of 34.42% and a 62% drop over one year, proportions that make the intraday surge difficult to qualify as a reversal.
The previous session had, moreover, been particularly volatile: the security had broken through its 2.62 € support down to a low of 2.55 €, before recovering above this level to close at 2.628 €. The breaking of the support, even temporarily, illustrates the fragility of the current configuration.
An RSI in extreme oversold at 16, well below all moving averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical indicators perspective, the company presents a highly degraded technical picture. The RSI is at 16, an extreme oversold level rarely reached, which reflects the accumulated selling exhaustion over several weeks. The price at 2.79 € remains well below its three moving averages: the MA20 is at 3.65 € (difference of -23.56%), the MA50 at 3.87 € (-27.91%) and the MA200 at 5.00 € (-44.20%). Such a gap to moving averages signals an uninterrupted underlying downtrend.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -95,8 %
Net income: -8,6 millions d'euros
Guidance from the release
visibilité financière maintenue jusqu'au début du deuxième trimestre 2027 ; incertitude significante sur la continuité d'exploitation
Risks mentioned
Consommation de trésorerie de 10,1 M€ au premier semestre 2026
Horizon de financement limité au début du deuxième trimestre 2027
Chiffre d'affaires semestriel en forte baisse, de 1 031 K€ à 43 K€
Opportunities identified
Résultats positifs de Phase 3 de BioChaperone® Lispro en Chine et dépôt d'AMM en préparation
Trois études de faisabilité BioChaperone® positives avec de grandes pharmas, deux en discussions avancées
AdOral® Sema breveté et libre d'exploitation alors que le semaglutide devient libre de droit en 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.